Because for many institutions, it is unlikely to make a big increase every day at the end of the year, and then create a wave of rapid bull market. Many institutions pursue stability and lock in this year's profit results.3. Generally speaking, today's shrinking and counter-pumping is basically formed, so it is ok to hold shares in the directions mentioned above.At this time, institutions will either choose some high dividends or some oversold industry leaders as a defense. Those who want to catch the daily limit and buy and sell in day trading are more likely to lose money.
For retail investors, today is still more suitable for holding shares to rise. If you bought yesterday, you don't have to worry about it in the short term. As long as you follow the above-mentioned directions of technology, consumption and real estate, at least the policy is supportive, and it is not chasing high in the short term.(2) Second, the appreciation of RMB exchange rate is obvious today. Yesterday's trend made everyone dissatisfied, but yesterday's exchange rate performance was very firm. Some people say that the exchange rate strength has anything to do with investors?It's not to say that every time I see a good thing or a big rise, I just want to buy it, so I may be chasing high every time.
The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.(1) First, there was an obvious shrinkage in the opening today. My understanding is that I bought what I should have bought yesterday and sold what I should have sold yesterday. Today, the market has risen, and everyone will not be so impulsive. Therefore, the main funds in the venue are self-directed.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.
Strategy guide
12-14
Strategy guide